DRMA (Dermata Therapeutics) Change In Inventory: $-0.09 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DRMA Dermata Therapeutics Inc DRMA
22 GF Score
Price $1.24
! 2 Warning Signs
View Full Analysis

What is Dermata Therapeutics Change In Inventory?

Dermata Therapeutics DRMA -4.26% 22 Change In Inventory is $-0.09 Mil as of Mar. 2026. GuruFocus rates DRMA with a GF Score™ of 22/100. The stock has 2 warning signs investors should review.

Dermata Therapeutics's change in inventory for the quarter that ended in Mar. 2026 was $-0.09 Mil. It means Dermata Therapeutics's inventory increased by $0.09 Mil from Dec. 2025 to Mar. 2026 .

Dermata Therapeutics's change in inventory for the fiscal year that ended in Dec. 2025 was $0.00 Mil. It means Dermata Therapeutics's inventory stayed the same from Dec. 2024 to Dec. 2025 .

Dermata Therapeutics's Total Inventories for the quarter that ended in Mar. 2026 was $0.09 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year. Dermata Therapeutics's Inventory Turnover for the quarter that ended in Mar. 2026 was 0.00.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Dermata Therapeutics  (NAS:DRMA) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Dermata Therapeutics's Days Inventory for the quarter that ended in is calculated as:

Days Inventory=Average Total Inventories/Cost of Goods Sold*Days in Period
=0.0465/0*365 / 4
=N/A

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Dermata Therapeutics's Inventory Turnover for the quarter that ended in Mar. 2026 is calculated as

Inventory Turnover=Cost of Goods Sold / Average Total Inventories
=0 / 0.0465
=0.00

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Dermata Therapeutics's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as

Inventory-to-Revenue=Average Total Inventories / Revenue
=0.0465 / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dermata Therapeutics Change In Inventory Related Terms

Dermata Therapeutics Change In Inventory Historical Data

* Premium members only.

The historical data trend for Dermata Therapeutics's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dermata Therapeutics Change In Inventory Chart

Dermata Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Inventory
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Dermata Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Change In Inventory Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -0.09
DRMA
22GF Score
Dermata Therapeutics Inc DRMA
Change In Inventory is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Dermata Therapeutics Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.09 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Inventory →
What does a Change In Inventory of $-0.09 Mil mean?
Dermata Therapeutics (DRMA) has a Change In Inventory of $-0.09 Mil as of Mar. 2026. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Dermata Therapeutics and its competitors.
Is Dermata Therapeutics' Change In Inventory too high?
Dermata Therapeutics' current Change In Inventory is $-0.09 Mil. Overall, Dermata Therapeutics has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Dermata Therapeutics' Change In Inventory compare to CURX and CELZ?
Dermata Therapeutics' Change In Inventory of $-0.09 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Inventory for a Biotechnology company?
A good Change In Inventory depends on the Biotechnology industry context. However, Change In Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Inventory mean?
A high Change In Inventory can signal that a stock is expensive relative to its fundamentals. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Dermata Therapeutics and its competitors. Dermata Therapeutics's current Change In Inventory is $-0.09 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dermata Therapeutics stock overvalued right now?
Dermata Therapeutics (DRMA) has a current Change In Inventory of $-0.09 Mil. The current Change In Inventory is $-0.09 Mil. Dermata Therapeutics' overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Inventory calculated?
Change In Inventory is calculated from a company's financial statements. For Dermata Therapeutics (DRMA), the current Change In Inventory is $-0.09 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Dermata Therapeutics Business Description

Address 3525 Del Mar Heights Road, No. 322, San Diego, CA, USA, 92130
Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin. The company's operates in one segment, which is the business of developing, branding, marketing, and commercializing direct to consumer skincare products.
22GF Score

Get the complete analysis for DRMA

Change In Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.24
Price